[International consensus] NAMS updates its position statement on osteoporosis in postmenopausal women

Yimaitong compiles and organizes, please do not reprint without authorization
.

Introduction: Recently, the North American Menopause Society (NAMS) issued a position statement reflecting the latest ideas and findings regarding the management of osteoporosis in postmenopausal women
.

 According to NAMS, since the last position statement on osteoporosis in 2010, significant progress has been made in the evaluation, prevention and treatment of osteoporosis in postmenopausal women
.

For example, bazedoxifene, a preparation that includes conjugated estrogen and non-progestin, has been approved for the prevention of osteoporosis
.

In addition, three targeted therapies have been approved to treat patients with osteoporosis at high risk of fractures
.

 About half of women over 50 years old will experience osteoporosis-related fractures, requiring life-long management.
According to the evidence provided in the position statement released this time, approximately half of women over 50 years old will or are experiencing osteoporosis-related fractures.
Torture of fractures
.

Although these fractures can seriously affect normal activities and quality of life, this problem has not received enough attention in diagnosis and treatment
.

 Menopausal estrogen deficiency is the main cause of bone loss.
Osteoporosis develops with age.
Even maintaining good nutritional intake and regular physical activity can only improve the situation, and it cannot be completely avoided.
Happen
.

At the same time, there is no cure for osteoporosis, so once diagnosed, lifelong management is required
.

 The new position statement proposes a new diagnosis and treatment strategy.
The position statement released this time believes that hormone therapy is the most suitable option for healthy women to prevent bone loss during menopause, especially for women with menopausal symptoms
.

 When measured during treatment, bone mineral density correlates with the patient’s current fracture risk
.

According to NAMS, this justifies the use of the hip T score as an appropriate clinical goal to guide treatment choices
.

 Although anti-remodeling drugs such as bisphosphonates and denosumab are used to treat most patients with osteoporosis, women with a very high fracture risk are advised to follow a new model of starting with bone building agents and then using anti-remodeling agents.
Remodeling agent treatment
.

 The statement also pointed out that it is necessary to adopt individualized and differentiated targeted diagnosis and treatment strategies for different patients, and that patient opinions should be incorporated into the decision-making process
.

 At the press conference, NAMS Medical Director Stephanie Faubion emphasized: “This new position statement on osteoporosis provides clinicians with practical guidelines for assessing and managing the bone health of postmenopausal women, and emphasizes personalized approaches, and Follow up and adjust regularly according to changing clinical needs and patient preferences"
.

 Yimaitong compiled and compiled from: North American Menopause Society.
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society[J].
Menopause (New York, NY), 2021, 28(9): 973- 997.